Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5745 induction and maintenance study in moderately to severely active ulcerative colitis
NL-OMON43698Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of andecaliximab in autoimmune colitis (3 arms), sponsored by Gilead Sciences. Primary endpoints: EBS clinical remission at Week 8, EBS clinical remission at Week 52 and 1 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
andecaliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON43698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43698.